Barclays Has Lowered Expectations for Pacira BioSciences (NASDAQ:PCRX) Stock Price

Pacira BioSciences (NASDAQ:PCRX - Free Report) had its price objective trimmed by Barclays from $25.00 to $17.00 in a research report released on Tuesday morning,Benzinga reports. The brokerage currently has an equal weight rating on the stock.

Several other equities analysts also recently weighed in on the company. JPMorgan Chase & Co. reiterated an "underweight" rating and set a $10.00 target price (down from $45.00) on shares of Pacira BioSciences in a research report on Monday, August 12th. Needham & Company LLC restated a "buy" rating and set a $22.00 price objective on shares of Pacira BioSciences in a report on Friday. Truist Financial lowered Pacira BioSciences from a "buy" rating to a "sell" rating and cut their target price for the company from $30.00 to $8.00 in a research report on Tuesday, August 13th. Piper Sandler downgraded shares of Pacira BioSciences from an "overweight" rating to a "neutral" rating and decreased their price target for the stock from $42.00 to $11.00 in a research report on Monday, August 12th. Finally, Jefferies Financial Group upped their price target on shares of Pacira BioSciences from $15.00 to $18.00 and gave the company a "buy" rating in a report on Tuesday, September 24th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $23.50.

Pacira BioSciences Trading Down 4.0 %

PCRX traded down $0.70 during trading on Tuesday, hitting $16.80. The company's stock had a trading volume of 732,373 shares, compared to its average volume of 860,346. Pacira BioSciences has a twelve month low of $11.16 and a twelve month high of $35.95. The stock has a market cap of $775.66 million, a PE ratio of -8.32 and a beta of 0.82. The firm's 50 day moving average price is $15.66 and its 200-day moving average price is $20.87. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 5.70.

Institutional Trading of Pacira BioSciences

Several hedge funds have recently added to or reduced their stakes in the business. Jane Street Group LLC increased its stake in shares of Pacira BioSciences by 1,780.2% during the first quarter. Jane Street Group LLC now owns 187,531 shares of the company's stock valued at $5,480,000 after acquiring an additional 177,557 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of Pacira BioSciences by 12.2% in the second quarter. Dimensional Fund Advisors LP now owns 1,828,065 shares of the company's stock valued at $52,300,000 after buying an additional 198,936 shares during the period. Legato Capital Management LLC raised its position in Pacira BioSciences by 74.0% in the second quarter. Legato Capital Management LLC now owns 52,913 shares of the company's stock worth $1,514,000 after acquiring an additional 22,497 shares in the last quarter. WINTON GROUP Ltd acquired a new position in shares of Pacira BioSciences in the 2nd quarter worth approximately $2,726,000. Finally, QRG Capital Management Inc. raised its holdings in shares of Pacira BioSciences by 42.0% in the 1st quarter. QRG Capital Management Inc. now owns 22,708 shares of the company's stock worth $664,000 after purchasing an additional 6,721 shares in the last quarter. Institutional investors own 99.73% of the company's stock.

About Pacira BioSciences

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.